Clinical benefits of empagliflozin in very old patients with type 2 diabetes hospitalized for acute heart failure

Autor: Jaime Sanz-Cánovas, Ricardo Gómez-Huelgas, Miguel Ángel Barbancho, Manuel F. Jiménez-Navarro, María Rosa Bernal-López, María D. López-Carmona, Mercedes Millán-Gómez, Almudena López-Sampalo, Michele Ricci, J.P. Lara, Julio Osuna-Sánchez, Luis M. Pérez-Belmonte
Rok vydání: 2021
Předmět:
Zdroj: Journal of the American Geriatrics Society. 70:862-871
ISSN: 1532-5415
0002-8614
DOI: 10.1111/jgs.17585
Popis: Background There is little evidence on the use of sodium-glucose cotransporter 2 (SGLT2) inhibitors in older patients with heart failure. This work analyzed the clinical efficacy and safety of empagliflozin continuation in very old patients with type 2 diabetes hospitalized for acute decompensated heart failure. Methods We conducted a real-world observational study between September 2015 and June 2021. Patients ≥80 years were grouped by antihyperglycemic regimen: (1) continuation of preadmission empagliflozin combined with basal insulin regimen and (2) conventional basal-bolus insulin regimen. A propensity score matching analysis matched patients in both groups in a 1:1 manner. The primary outcome was differences in clinical efficacy measured by the visual analogue scale dyspnea score, NT-proBNP levels, diuretic response, and cumulative urine output. Safety endpoints such as adverse events, worsening heart failure, discontinuation of empagliflozin, length of hospital stay, and in-hospital deaths were also analyzed. Results After propensity score matching, 79 patients were included in each group. At discharge, the N-terminal pro-brain natriuretic peptide (NT-proBNP) levels were lower in the empagliflozin continuation group than in the insulin group (1699 ± 522 vs. 2303 ± 598 pg/ml, p = 0.021). Both the diuretic response and cumulative urine output were greater in patients treated with empagliflozin than in patients with basal-bolus insulin during the hospitalization (at discharge: -0.14 ± -0.06 vs. -0.24 ± -0.10, p = 0.044; and 16,100 ± 1510 vs. 13,900 ± 1220 ml, p = 0.037, respectively). No differences were observed in safety outcomes. Conclusions In very old patients with type 2 diabetes hospitalized for acute heart failure, continuing preadmission empagliflozin reduced NT-proBNP levels and increased diuretic response and urine output compared to a basal-bolus insulin regimen. The empagliflozin regimen also showed a good safety profile.
Databáze: OpenAIRE
Externí odkaz: